Omeprazole/amoxicillin/rifabutin
This article will address the topic of Omeprazole/amoxicillin/rifabutin, which has been the subject of interest and debate in various areas. Since time immemorial, Omeprazole/amoxicillin/rifabutin has aroused the curiosity and intrigue of humanity, generating both admiration and controversy. Throughout history, Omeprazole/amoxicillin/rifabutin has played a significant role in society, influencing the way people relate to and perceive their environment. In this sense, it is essential to thoroughly analyze and understand the multiple facets of Omeprazole/amoxicillin/rifabutin, with the aim of expanding our knowledge and vision of the world around us. In this way, we aim to shed light on the various implications and repercussions that Omeprazole/amoxicillin/rifabutin has had and continues to have today.
| Combination of | |
|---|---|
| Omeprazole | Proton-pump inhibitor |
| Amoxicillin | Penicillin-class antibacterial |
| Rifabutin | Rifamycin antibacterial |
| Clinical data | |
| Trade names | Talicia |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Omeprazole/amoxicillin/rifabutin, sold under the brand name Talicia, is a fixed-dose combination medication used for the treatment of Helicobacter pylori infection. It is taken by mouth.
It was approved for medical use in the United States in November 2019.
References
- ^ a b c "Talicia- omeprazole magnesium, amoxicillin and rifabutin capsule, delayed release". DailyMed. Retrieved 4 October 2021.
- ^ "Drug Approval Package: Talicia". U.S. Food and Drug Administration (FDA). 9 April 2020. Retrieved 4 October 2021.
External links
- "Omeprazole". Drug Information Portal. U.S. National Library of Medicine.
- "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine.
- "Rifabutin". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03198507 for "ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2)" at ClinicalTrials.gov
- Clinical trial number NCT01980095 for "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (ERADICATE Hp)" at ClinicalTrials.gov
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |